Prof. Emma Edmond Keuleyan

Co-authors

Following

Followers

Research Focus & Metrics

Explore full metrics on Scilit

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2008 in Antimicrobial Agents and Chemotherapy

Journal Article

VIM-15 and VIM-16, Two New VIM-2-Like Metallo-β-Lactamases in Pseudomonas aeruginosa Isolates from Bulgaria and Germany

Ines Schneider

Emma Edmond Keuleyan

Rudolf Rasshofer

Rumyana Markovska

Anne Marie Queenan

Adolf Bauernfeind

Two Pseudomonas aeruginosa urine isolates from Bulgaria and Germany produced two new VIM-2 variants. VIM-15 had one amino acid substitution (Tyr218Phe) which caused a significant increase in hydrolytic efficiency. The substitution Ser54Leu, characterizing VIM-16, showed no influence on enzyme activity. Both genes were part of class I integrons located in the chromosome.

1 June 2008 in Microbial Drug Resistance

Journal Article

Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae in Bulgarian Hospitals

Rumyana Markovska

Ines Schneider

Emma Edmond Keuleyan

Mariya Sredkova

Dobrinka Ivanova

Adolf Bauernfeind

The aim of the study was to describe the emergence, the spread, and the prevalence of extended-spectrum β-lactamase (ESBL)–producing Enterobacteriaceae in Bulgaria. Over eight years (1996–2003), 442 ESBL-screen-positive isolates were collected in nine medical institutions in four Bulgarian towns. Class A ESBLs of the SHV, TEM, and CTX-M groups were identified in seven species. SHV-type enzymes persisted during the whole study period, TEM-ESBLs appeared first in 1999, and CTX-M–types appeared first in 2001. The rate of CTX-M enzyme producers increased rapidly between 2001 and 2003, while the rate of SHV producers decreased. Six different ESBL-types were identified, namely, SHV-2, −5, and −12, CTX-M-3 and −15, and a new TEM-3–like variant (TEM-139). The most widespread enzymes were SHV-12, CTX-M-15, and CTX-M-3 found in seven centers. TEM-139 was identified mainly in one center. A trend for strains harboring more than one ESBL gene, for example, CTX-M + SHV, was observed since 2002. Plasmid fingerprinting and random amplified polymorphic DNA analysis typing revealed wide dissemination of identical plasmids among different bacterial species and hospitals, as well as clonal spread of ESBL producers. Our data contribute to clarify the dynamics in the prevalence of ESBLs in Bulgaria and demonstrate the importance of molecular procedures for their analysis.

1 September 2004 in International Journal of Antimicrobial Agents

Journal Article

Antibiotic policies in Central Eastern Europe

MČ

Milan Čižman

Bojana Beovic

Vladimir Krcmery

Bruno Barsic

Eda Tamm

Peter Dvorák

+11

1 August 2004 in Clinical Microbiology and Infection

Journal Article

Extended-spectrum β-lactamase (ESBL) CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae in Sofia, Bulgaria

Rumyana Markovska

I. Schneider

Emma Edmond Keuleyan

A. Bauernfeind

During a survey of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in Bulgaria in 2001–2002, three isolates from Sofia (two Escherichia coli, one Klebsiella pneumoniae) showed cefotaxime MICs that were decreased in the presence of clavulanate and were 2–8-fold higher than those of ceftazidime. Resistance was transferred to a sensitive recipient strain of E. coli. Both wild-type and transconjugant strains produced a cefotaxime-hydrolysing β-lactamase of pI 8.8. Sequencing of the PCR product obtained with oligonucleotide primers binding outside the coding region identified this β-lactamase as CTX-M-15. To our knowledge, this is the first report of CTX-M-15 in Bulgaria.

1 December 2001 in Clinical Microbiology and Infection

Journal Article

Key issues in developing antibiotic policies: from an institutional level to Europe-wide. European Study Group on Antibiotic Policy (ESGAP), Subgroup III

Emma Edmond Keuleyan

I.M. Gould

1 April 2017 in Microbial Drug Resistance

Journal Article

Dissemination of a Multidrug-Resistant VIM-1- and CMY-99-Producing Proteus mirabilis Clone in Bulgaria

Rumyana Markovska

Ines Schneider

Emma Edmond Keuleyan

Dobrinka Ivanova

Magdalena Lesseva

Ivan Mitov

The aim of this study was to analyze the beta-lactamases and the molecular epidemiology of 19 clinically significant isolates of Proteus mirabilis with decreased susceptibility to imipenem, which have been collected from seven hospitals, located in different Bulgarian towns (Sofia, Varna, and Pleven). The isolates were obtained from blood, urine, tracheal and wound specimens. One additional isolate from hospital environment was included. Susceptibility testing, conjugation experiments, and plasmid replicon typing were carried out. Beta-lactamases were characterized by isoelectric focusing, PCR, and sequencing. Clonal relatedness was investigated by RAPD and PFGE. Integron mapping was performed by PCR and sequencing. All isolates showed a multidrug-resistance profile, but remained susceptible to piperacillin/tazobactam, cefepime, meropenem, and fosfomycin. They produced identical beta-lactamases, namely: TEM-1, VIM-1, and CMY-99. PCR mapping revealed that the bla _VIM-1 gene was part of a class 1 integron that additionally included the aac(6′)-I, dhfrA1 , and ant(3″)-Ia genes. In addition, 17 of the isolates carried the armA gene. Conjugation experiments and plasmid replicon typing were unsuccessful. The isolates were clonally related according to RAPD and PFGE typing. This study reveals the nationwide distribution of a multidrug-resistant P. mirabilis clone producing VIM-1 and CMY-99 along with the presence of different aminoglycoside resistance mechanisms.

About Me

Prof. Emma Keuleyan, MD, PhD is Head of the Laboratory for Clinical Microbiology and Virology at University Hospital Lozenetz and expert-conductor at the Directorate “Public Health” of the Ministry of Health of Bulgaria. She graduated from the Medical Academy in Sofia and has specialized in France, the Netherlands, the United Kingdom, and India. Prof. Keuleyan is a specialist in clinical microbiology, antimicrobial resistance, infection prevention and control, and rapid microbiological diagnostics. She defended her PhD thesis on aminoglycoside resistance in clinically significant Gram-negative bacteria and was subsequently elected associate professor and professor in microbiology. She is author/co-author of over 395 scientific publications with more than 1,500 citations and recipient of several international awards, including the Dr. M. Rogosa Award of the American Society for Microbiology. Prof. Keuleyan is an active member of Bulgarian and international scientific societies, including European Society of Clinical Microbiology and Infectious Diseases, and currently contributes to the EU-JAMRAI-2 project on antimicrobial resistance. Her recent research focuses on antimicrobial stewardship, antibiotic resistance, healthcare-associated infections, and emerging microbial pathogens. She has two publications in MDPI: - https://doi.org/10.3390/antibiotics13010081, - https://doi.org/10.3390/ microorganisms13010179 ORCID: 0000-0003-2641-6453

Prof. Emma Edmond Keuleyan

Prof. Emma Edmond Keuleyan

Research Focus & Metrics

Academic Career Length

Publication Type Breakdown

Representative Publications

About Me